“The definition of promising clinical activity has to be based on survival rather than response rates … the higher response rates haven't translated into survival improvements,” he said.
Dr. Middleton and Dr. Eggermont have received research funding from and are consultants to Schering-Plough. Dr. Eggermont is a consultant to Bayer, Boehringer Ingelheim, GlaxoSmithKline, Sanofi Pasteur, Onyx Pharmaceuticals, Genta Inc., and Synta Pharmaceuticals. Dr. Lebbé has received Novartis research funding.
'The CTLA4 antibodies arethe mostexciting agentson the horizon.' DR. EGGERMONT
Clinical activity must be based on survival, and not response rates, which have not translated into improved survival. DR. MIDDLETON